Navigation Links
Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression

COPENHAGEN, Denmark, June 04, 2007 /PRNewswire/ --

- Cipralex Better Tolerated and at Least as Effective in Long-Term Treatment

H. Lundbeck A/S announces new study data published today in the journal Current Medical Research and Opinion, demonstrating that Cipralex(R) (escitalopram) was superior to duloxetine in the acute treatment of patients with major depressive disorder (MDD) and was at least as efficacious in long-term treatment(1). The study directly compared Cipralex(R) (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (the most recently introduced serotonin and noradrenaline reuptake inhibitor - SNRI) and these findings support the growing body of evidence that Cipralex(R) offers important treatment advantages over SNRI antidepressants such as duloxetine(2-6).

Depression is a serious illness that results in significant disability and is associated with both increased morbidity and the risk of suicide(7). Affecting around 121 million people globally(8,) the World Health Organization lists depression as the leading cause of disability worldwide(8). At present, there is no simple universal treatment effective for all patients and it is therefore relevant that treatments are directly compared in order to provide clinicians with information on the efficacy and tolerability benefits of the currently available treatments.

"The study demonstrates that Cipralex(R) was superior to duloxetine during acute treatment and at least as effective in long-term treatment with the added benefit of significantly better tolerability," said Dr Alan Wade, lead investigator and medical director of CPS Research, Glasgow, Scotland. "Data that compares antidepressants in this way is an important tool for physicians and allows them to make informed decisions about the best treatments for their patients."

Important key findings from the study:

The 24-week study investigated t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)... -- The American Association for Homecare (AAHomecare) yesterday announced ... address audit issues in the HME industry through ... information technology lead in shaping its HME Audit ... and business management solutions for nearly 3,000 providers, ... this important initiative on behalf of all HME ...
(Date:7/24/2014)... 24, 2014 Decision Resources Group finds that, ... countries ( France , Germany ... Spain and the United Kingdom ... first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination ... Relvar as a first-line LABA/ICS FDC in the treatment ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Colo., April 26, 2012 /PRNewswire-iReach/ -- ... solutions, announces the availability of the Vending Fridge. ... lets consumers use a simple QR code scanner ... App to seamlessly purchase refrigerated products. The Vending ...
... April 26, 2012  IDenta Corp. (OTC: IDTA) CEO Yaacov Shoham ... released to OTC Markets the following files and asked them ... OTC Disclosure & News Service section." 1. Annual ... 2. Initial Company Information and Disclosure Statement ...
Cached Medicine Technology:ShelfX Releases A Fridge That Knows What You Took 2International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets. 2
(Date:7/24/2014)... who received the Human Papillomavirus Vaccination (HPV) even ... abnormal Pap test results than those who were ... Sexually Transmitted Diseases . , Researchers ... School of Medicine conducted a cross-sectional study of ... cervical cytology testing. HPV status and demographic and ...
(Date:7/24/2014)... Los Angeles, CA (PRWEB) July 24, 2014 ... (FDA), American Optometric Association (AOA) and the Entertainment ... artists from the TV series American Horror Story ... to bring the dramatic realities of illegal ... public service campaign, which has already reached tens-of-thousands, ...
(Date:7/24/2014)... the 4th Annual National Venous Interventional Summit is ... is an established Venous Endovascular Interventional Strategies group ... aim is to provide a "How To" meeting ... interested in advancing their knowledge and skills in ... their own comprehensive venous interventional program. Topics at ...
(Date:7/24/2014)... Metastasis, the strategy adopted by tumor cells to transform ... with a gloomy prognosis. Managing to block the metastasis ... giant step towards the fight against cancer. Researchers at ... first on models of human tumors in mice. ... 24 July in the prestigious journal Cell Reports ...
(Date:7/24/2014)... together to spread further and faster, according to a ... lead to new drugs to tackle melanoma, the most ... scientists at The University of Manchester found that some ... good at invading the surrounding tissue, while other melanoma ... , In a tumour, the faster growing cells ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:A world first: Researchers identify a treatment that prevents tumor metastasis 2Health News:Piggy-backing cells hold clue to skin cancer growth 2
... Asking emergency department patients about their alcohol use ... harmful drinking patterns is an effective way to ... according to a nationwide collaborative study supported by ... (NIAAA) and the Substance Abuse and Mental Health ...
... ARLINGTON, Va., Dec. 26 For every Seung ... make headlines.,More at http://www.treatmentadvocacycenter.org ., -- ... health system has failed.,To get to one of ... to commit,a crime. The courts are like wheelchairs ...
... in Nyer Medical Group;, President of subsidiary to become ... Maine, Dec. 26 Nyer Medical Group,Inc. (Nasdaq: ... with the,minority shareholders of its subsidiary, D.A.W., Inc. d/b/a ... pharmacy chain in,fulfillment of Nyer,s obligation pursuant to a ...
... 012,Smile.Communications (NASDAQ Global market and TASE: SMLC), a,growth-oriented ... it has been chosen by Sheba Medical Center ... Access system for the use of its,doctors, staff, ... the contract, 012 Smile.Communications will,design, install, manage and ...
... chemotherapy drugs called anthracyclines improves survival in women ... surgery, but it may not offer any benefit ... study published online December 25 in the ... , Randomized clinical trials have demonstrated that treating ...
... green spaces close to your zip code , TUESDAY, Dec. ... nature,s beauty that Christmas evergreen in your living room this ... developed a Web-based tool to help you find live evergreens ... great outdoors in green places close to your zip code. ...
Cached Medicine News:Health News:Brief intervention helps emergency patients reduce drinking 2Health News:Brief intervention helps emergency patients reduce drinking 3Health News:Treatment Advocacy Center's Top 10 Mental Illness Stories You Didn't Read in 2007 2Health News:Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary 2Health News:Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary 3Health News:012 Smile.Communications to Deploy Extensive WiFi Internet Access System for Sheba Medical Center 2Health News:012 Smile.Communications to Deploy Extensive WiFi Internet Access System for Sheba Medical Center 3Health News:Anthracyclines improve survival in HER2-positive breast cancer patients 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: